Results 31 to 40 of about 922,822 (266)
Metastatic renal cancer: real-world evidence from a large Italian claims database
Purpose: To assess the healthcare resources’ consumption and integrated costs of patients with renal cancer and new metastasis (mRCC), in the perspective of the Italian National Health System (NHS).
Giulia Ronconi +9 more
doaj +1 more source
This essay analyses the evolution of the National Health Service (NHS) in Italy after the beginning of the financial crisis of 2008, focusing on some trajectories of change underway in the NHS governance.
Stefano Neri
doaj +1 more source
Background The status of health of an individual and - more broadly - of a community or population is defined by the status of their determinants of health.
Domenico Tebala +1 more
doaj +1 more source
Pharmaceutical industry investments in Italy must be supported with a reform process that promotes simplifications to generate an attractive ecosystem that can enhance innovation.
Francesca Patarnello +2 more
doaj +1 more source
Outsourcing in the Italian NHS: a Measure of Mismatch Between Private and Public Operators [PDF]
Outsourcing is a useful tool for improving partnership between private and public companies. The budgetary constraints recently imposed by the Italian government on health industry are enhancing the urgency to outsource to face costs. Our study deals with the relationship between ASLs (Aziende Sanitarie Locali, the Italian local health authorities) and
MARIANI, PAOLO +3 more
openaire +6 more sources
A cost-minimization analysis of MD-Knee versus hyaluronic acid in patients with knee osteoarthritis
Introduction: The administration by injection of hyaluronic acid (HA) for 3-5 weeks is effective in the treatment of patients with knee osteoarthritis (OA).
Alberto Migliore, Roberto Ravasio
doaj +1 more source
A Budget impact analysis of adalimumab biosimilar: the Italian context
Introduction: Patients’ quality of life impairment together with a heavy burden to the NHS and society are caused by chronic inflammatory diseases. Their treatment substantially improved with the advent of biological drugs (such as adalimumab), but these
Roberto Ravasio +4 more
doaj +1 more source
Objective: The aim of this economic evaluation was to assess the cost-utility of brigatinib versus alectinib in the treatment of naïve patients to anaplastic lymphoma kinase-positive advanced non-small cell lung cancer (ALK-positive aNSCLC) from the ...
Roberto Ravasio +4 more
doaj +1 more source
Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia
Background: The current clinical practice for patients affected by chronic myeloid leukemia (CML) is based on the evaluation of second generation alternatives following therapeutic failure that leads to a lengthening of patients’ management times and a ...
Michele Basile +2 more
doaj +1 more source
Purpose: The objective of this economic evaluation was to compare the cost per responder between upadacitinib and abatacept (intravenous [iv] or subcutaneous [sc]) in patients with moderate-to-severe Rheumatoid Arthritis (RA) in Italy.
Roberto Caporali +3 more
doaj +1 more source

